West Pharmaceutical Services posted a solid Q2, with revenue and adjusted earnings per share exceeding Wall Street expectations, while the market response remained muted. Management attributed the outperformance to robust growth in its Proprietary Products, particularly high-value product (HVP) components for biologics and biosimilars. CEO Eric Green highlighted, “Our performance was driven by the execution of our strategy and continued operational excellence initiatives,” pointing to the company’s strong recovery following a cyber incident and the expansion of advanced containment solutions as key factors supporting the quarter.
Is now the time to buy WST? Find out in our full research report (it’s free).
West Pharmaceutical Services (WST) Q2 CY2026 Highlights:
-
Revenue: $872.3 million vs analyst estimates of $842.7 million (13.8% year-on-year growth, 3.5% beat)
-
Adjusted EPS: $2.37 vs analyst estimates of $2.08 (13.9% beat)
-
The company lifted its revenue guidance for the full year to $3.36 billion at the midpoint from $3.32 billion, a 1.2% increase
-
Management raised its full-year Adjusted EPS guidance to $8.95 at the midpoint, a 4.4% increase
-
Operating Margin: 20.5%, in line with the same quarter last year
-
Market Capitalization: $23.75 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call
-
Michael Ryskin (Bank of America): asked about the sustainability of non-GLP-1 HVP component growth. CEO Eric Green explained that strong biologics pipelines, regulatory-driven upgrades, and operational resilience underpin the momentum, calling it a “multiyear opportunity.”
-
Paul Knight (KeyBanc): inquired about capacity utilization at major facilities. Green detailed productivity improvements at Eschweiler, nearing target utilization at Grand Rapids, and ongoing ramp-up at Dublin, with full capacity expected to be leveraged in coming quarters.
-
Patrick Donnelly (Citi): questioned margin expansion drivers for the second half. CFO Robert McMahon pointed to pricing momentum, product mix shift, and operational leverage as key factors, and suggested further upside is possible with ongoing initiatives.
-
Daniel Markowitz (Jefferies): asked whether guidance assumes a slowdown in GLP-1 component demand. McMahon clarified the outlook reflects prudent forecasting, not a market slowdown, and that international generic launches will be a bigger driver in future years.
-
Kallum Titchmarsh (Morgan Stanley): sought specifics on Asia Pacific growth. Green highlighted China and India as primary contributors, particularly in GLP-1 biosimilars, with South Korea showing increasing innovation and contract manufacturing activity.